Bausch Health Companies Inc. BHC
We take great care to ensure that the data presented and summarized in this overview for Bausch Health Companies Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BHC
View all-
Icahn Carl C Sunny Isles Beach, FL34.7MShares$236 Million3.29% of portfolio
-
Goldentree Asset Management LP New York, NY27.6MShares$188 Million23.66% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny26.4MShares$180 Million20.29% of portfolio
-
Franklin Resources Inc San Mateo, CA15.9MShares$108 Million0.06% of portfolio
-
National Bank Of Canada15.7MShares$106 Million0.29% of portfolio
-
Nomura Holdings Inc Tokyo, M015.4MShares$105 Million0.42% of portfolio
-
Healthcare Of Ontario Pension Plan Trust Fund Toronto, A613MShares$88.4 Million0.48% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT11.8MShares$79.9 Million0.77% of portfolio
-
Royal Bank Of Canada Toronto, A611.7MShares$79.7 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$79.7 Million0.0% of portfolio
Latest Institutional Activity in BHC
Top Purchases
Top Sells
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Insider Transactions at BHC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 20
2024
|
John S Barresi SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,930
-1.8%
|
$11,580
$6.73 P/Share
|
May 17
2024
|
Christian A Garcia Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+50.0%
|
-
|
May 17
2024
|
Frank D. Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+50.0%
|
-
|
May 17
2024
|
Robert N Power Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+15.0%
|
-
|
May 17
2024
|
Amy B Wechsler Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+14.7%
|
-
|
May 17
2024
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+12.67%
|
-
|
May 17
2024
|
Sarah B Kavanagh Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+16.27%
|
-
|
May 17
2024
|
Steven D Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+16.82%
|
-
|
May 17
2024
|
Brett Icahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,360
+19.73%
|
-
|
Mar 29
2024
|
Russel C Robertson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,945
+1.29%
|
$29,450
$10.61 P/Share
|
Mar 29
2024
|
Brett Icahn Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,122
+2.8%
|
$31,220
$10.61 P/Share
|
Mar 29
2024
|
John Paulson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,890
+2.75%
|
$58,900
$10.61 P/Share
|
Mar 29
2024
|
Amy B Wechsler Director |
BUY
Grant, award, or other acquisition
|
Direct |
647
+0.38%
|
$6,470
$10.61 P/Share
|
Mar 04
2024
|
Seana Carson EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,313
-0.31%
|
$56,817
$9.8 P/Share
|
Mar 01
2024
|
John S Barresi SVP, Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,188
-2.89%
|
$28,692
$9.89 P/Share
|
Mar 01
2024
|
Seana Carson EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
24,243
-1.15%
|
$218,187
$9.89 P/Share
|
Mar 01
2024
|
Thomas Appio Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
116,982
-2.0%
|
$1,052,838
$9.89 P/Share
|
Feb 29
2024
|
John S Barresi SVP, Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
39,126
+26.19%
|
-
|
Feb 29
2024
|
Seana Carson EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
147,536
+21.76%
|
-
|
Feb 29
2024
|
Thomas Appio Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
519,328
+25.89%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.05M shares |
---|
Payment of exercise price or tax liability | 262K shares |
---|---|
Open market or private sale | 13.3K shares |